STAT is Live-Blogging Sickle Cell Hearing: 'Barbed Critique' from FDA official on Proposed Gene Therapy
Patients praise treatment, FDA official takes deep dive into off-target risk
The respected health and medical news service STAT is live-blogging today’s FDA hearing on Vertex’s and Crispr Therapeutic’s proposed gene therapy for sickle cell disease.
An advisory panel is examining possible off-target risks involved in the therapy. Patients and scientists have testified. Here is the most recent blog offering from STAT. The hearin…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.